ASCO 2017 WEBCAST. Elacestrant (RAD1901) June, 4, 2017
|
|
- Loreen Wilson
- 6 years ago
- Views:
Transcription
1 ASCO 2017 WEBCAST Elacestrant (RAD1901) June, 4, 2017 NASDAQ: RDUS Disclaimer: RAD1901 is an investigational agent Please refer to the ASCO 2017 poster for complete details
2 Safe Harbor Any statements made in this presentation relating to future financial or business performance, conditions, plans, prospects, trends or strategies and other financial or business matters, including expectations regarding the development and potential commercialization of our product candidates, clinical trial results, regulatory actions, potential collaborations, future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of In addition, when used in this presentation, the words may, could, should, anticipate, believe, estimate, expect, intend, plan, predict, target and similar expressions and their variants, as they relate to Radius Health, Inc. ( Radius ) or its management, may identify forward-looking statements. Radius cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include, without limitation, risks and uncertainties regarding the progress of abaloparatide-sc in the regulatory process in Europe and the timing of potential regulatory actions; progress in the development of our product candidates; our failure to secure and maintain relationships with collaborators; risks relating to clinical trials; risks relating to the commercialization of TYMLOS in the U.S., or potential commercialization of any of our proposed product candidates, if approved (such as marketing, regulatory, patent, product liability, supply, competition and other risks); dependence on the efforts of third parties; dependence on and potential challenges to our intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect Radius business, financial conditions and results of operations and could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation are contained under the caption risk factors in Radius Annual Report on Form 10-K for the period ended December 31, 2016, filed with the U.S. Securities and Exchange Commission (SEC) on February 24, 2017, along with Radius most recent quarterly and other reports filed with the SEC. The forward-looking statements represent Radius estimate as of the date of this presentation only, and Radius specifically disclaims any duty or obligation to update forward-looking statements. 2
3 Agenda 3 TOPIC Welcome PRESENTER Barbara Ryan, IR Elacestrant Update Breast Cancer Treatment Landscape Alison O Neill, MD, VP, Oncolcgy Clinical Development Gary Hattersley, PhD, Scientific Officer Commercial Opportunity Robert Ward, President and CEO Q&A 3
4 Elacestrant Update Maturing data presented at ASCO 2017 on the US Ph1 Dose Escalation & Expansion study Data Presented at ASCO 2017 Impressive single agent activity in heavily pre-treated ER+ breast cancer patients Objective Response Rate (ORR) of 23% in patients with RECIST measurable disease at baseline Clinical Benefit Rate (CBR) at 24 weeks of 42%* Median Progression Free Survival (mpfs) of 4.5 months* Responses documented in patients with prior fulvestrant therapy, prior CDK4/6i therapy and in patients with ESR1 mutations 15 patients continue on treatment as of April 28, 2017 * In patient group with mature data for estimation (Parts A+B) 4
5 Evaluation of elacestrant (RAD1901), a novel oral investigational, selective estrogen receptor degrader (SERD), for the treatment of ER positive (ER+) advanced breast cancer (mbc) Aditya Bardia 1, Peter Kabos 2, Richard Elledge 3, Dannie Wang 4, Jinshan Shen 4, Fiona Garner 4, Alison O'Neill 4, Virginia G. Kaklamani 3 1 Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA; 2 University of Colorado Denver, Greenwood Village, CO; 3 CTRC, University of Texas Health Science Center San Antonio, San Antonio, TX; 4 Radius Health Inc., Waltham, MA 5
6 Phase 1 dose escalation and expansion study design Study Objectives Primary: define recommended Phase 2 dose Secondary: safety and tolerability, pharmacokinetics (PK), preliminary anti-tumor effect, and evaluation of circulating tumor DNA (ctdna; exploratory objective) Response evaluations performed every 8 weeks following RECIST v1.1 guidelines Patient population ER+/HER2- postmenopausal women with mbc 2 prior chemotherapies in the advanced or metastatic setting No limit on number of prior endocrine therapies 6
7 Patient Demographics Median of 3 prior systemic therapies 38% had previously received fulvestrant 40% had previously received CDK4/6 inhibitor therapy 30% had received >1 prior line of chemotherapy 50% were ESR1 mutant 7
8 Objective Response Rates (ORR) in ER+ Advanced Breast Cancer for Endocrine Agents Range from 2.1%* (mono) to 19%* (in combo) 25% SERD combo mtor combo 3 rd line 0% 7-9% Fulvestrant (SOFEA, PALOMA-3) 2.1% Fulvestrant (BELLE-3) monotherapy ORR *ORR is based on ITT 8
9 Objective Response Rates (ORR) in ER+ Advanced Breast Cancer for Endocrine Agents Range from 2.1%* (mono) to 19%* (in combo) 25% SERD combo mtor combo 3 rd line 0% 19% Fulvestrant +Palbociclib (PALOMA-3) 9.5% Exemestane + Everolimus (BOLERO-2) 7-9% Fulvestrant (SOFEA, PALOMA-3) 2.1% Fulvestrant (BELLE-3) monotherapy combinations ORR *ORR is based on ITT 9
10 Elacestrant single agent ORR 23% in heavily pre-treated patients 22 patients had RECIST measurable disease 5 confirmed partial responses 9 patients with stable disease Confirmed responses observed in patients with prior fulvestrant, prior CDK4/6i therapy, and ESR1mut as well as wildtype 10
11 Clinical Benefit Rates (CBR) in ER+ Advanced Breast Cancer for Endocrine Agents Range from 15.4%* (mono) to 67%* (in combo) 70% SERD combo mtor combo 3 rd line 0% CBR 32-40% Fulvestrant (SOFEA, PALOMA-3) 15.4% Fulvestrant (BELLE-3) monotherapy *CBR is based on ITT 11
12 Clinical Benefit Rates (CBR) in ER+ Advanced Breast Cancer for Endocrine Agents Range from 15.4%* (mono) to 67%* (in combo) 70% SERD combo mtor combo 3 rd line 0% CBR 67% Fulvestrant +Palbociclib (PALOMA-3) 51.3% Exemestane + Everolimus (BOLERO-2) 32-40% Fulvestrant (SOFEA, PALOMA-3) 15.4% Fulvestrant (BELLE-3) monotherapy combinations *CBR is based on ITT 12
13 Elacestrant single agent CBR at 24 weeks 42% in patient group with mature data set (Parts A+B) Fulv = prior fulvestrant treatment; CDK4/6 = prior CDK4/6 inhibitor treatment; ESR1 = ESR1 mutation detected at baseline; RECIST = patients with RECIST measurable disease. Radius Health, Inc. PROPRIETARY
14 Median Progression Free Survival (mpfs) in ER+ Advanced Breast Cancer for Endocrine Agents Range from 1.8 mo* (mono) to 9.5 mo* (in combo) 10 mo SERD combo mtor combo 3 rd line mo Fulvestrant (PALOMA-3, SOFEA ) 1.8 mo Fulvestrant (BELLE-3) monotherapy mpfs *mpfs is based on ITT 14
15 Median Progression Free Survival (mpfs) in ER+ Advanced Breast Cancer for Endocrine Agents Range from 1.8 mo* (mono) to 9.5 mo* (in combo) 10 mo SERD combo mtor combo 9.2 mo Fulvestrant +Palbociclib (PALOMA-3) 7.8 mo Exemestane + Everolimus (BOLERO-2) combinations 3 rd line mo Fulvestrant (PALOMA-3, SOFEA ) 1.8 mo Fulvestrant (BELLE-3) monotherapy mpfs *mpfs is based on ITT
16 Elacestrant single agent mpfs 4.5 months in patient group with mature data set (Parts A+B*) *400 mg tablet data (Part C patients) is not mature for CBR or PFS estimates at this time **CBR at 24 weeks was calculated using the CBR population (ie. all 400mg patients in Part A+B who had at least 1 post baseline RECIST evaluation) 16
17 Most common ( 10%) treatment-related adverse events Elacestrant 400 mg administered orally on a continuous daily schedule was well tolerated Longest 400mg treatment duration now exceeds 1 year Predominantly G1 and G2 upper GI events (nausea, dyspepsia, vomiting) Profile supportive of potential for combination with other agents The two patients with G3 transaminase elevations had liver metastases; elevations were transient in one and associated with progressive disease in the liver in the second Radius Health, Inc. PROPRIETARY 17
18 What is an IDEAL profile for a SERD? Targeted potent ER receptor degrader Effective in treating resistant disease including ESR1 mutants Safety profile that allows for drug combinations eg: SERD+ CDKi s PK profile that allows for once a day oral dosing 18
19 Elacestrant Demonstrates Complete ERa Degradation Comparison with Other Investigational SERDs Human ER+ Breast Cancer Cell Line (MCF7) Cells were treated for 48 hours RAD1901 (nm) AZD9496 (nm) RAD1901 (nm) GDC-0810 (nm) RAD1901 (nm) Bazedoxifene (nm) V V V ERα Vinculin Elacestrant has shown superior activity than comparator oral SERDs 19
20 Elacestrant Demonstrates Complete Tumor Growth Inhibition Comparison with Other Investigational SERDs ESR1 Mutant Fulvestrant-Resistant Patient Derived Xenograft Model F u lv e s tra n t C o n tr o l G D C PDX: ST941 Patient Rx history: Aromatase inhibitor ESR1: Y537S T u m o r V o lu m e (m m 3 ) A Z D Fulvestrant: 3mg/dose every week Elacestrant: 60mg/kg daily GDC-810: 100mg/kg daily AZD9496: 5mg/kg daily Comparable to current clinical doses Produces greatest efficacy in models E la c e s tra n t D a y Elacestrant has shown superior suppression of tumor growth compared to fulvestrant, AZD9496, and GDC
21 Potential Combination Targets for SERDs Targeted therapies may be combined with Elacestrant (RAD1901) to improve clinical outcomes PI3K Inhibitors mtor Inhibitors Immuno- Oncology Agents CDK Inhibitors SERD PARP Inhibitors BCL2 Inhibitors HDAC Inhibitors 21
22 Elacestrant as a BEST in class SERD Elacestrant demonstrates complete ER degradation ü Elacestrant inhibits tumor growth in resistant models, including those that are ESR1 mutant ü Elacestrant has a well tolerated safety profile ü Elacestrant has a PK profile that supports once a day oral dosing ü 22
23 Elacestrant Update Maturing data presented at ASCO 2017 on the US Ph1 Dose Escalation & Expansion study Data Presented at ASCO 2017 Impressive single agent activity in heavily pre-treated ER+ breast cancer patients Objective Response Rate (ORR) of 23% in patients with RECIST measurable disease at baseline Clinical Benefit Rate (CBR) at 24 weeks of 42%* Median Progression Free Survival (mpfs) of 4.5 months* Responses documented in patients with prior fulvestrant therapy, prior CDK4/6i therapy and in patients with ESR1 mutations 15 patients continue on treatment as of April 28, 2017 * In patient group with mature data for estimation (Parts A+B) 23
24 Endocrine therapies in second line advanced breast cancer phase III trials Ther Adv Med Oncol 2015, Vol. 7(6)
25 Hormone Receptor Positive Breast Cancer and potential value of an ORAL SERD Hormonal Therapies and Development of Endocrine Resistance Adjuvant 1 st Line 2 nd Line 3 rd Line Tamoxifen Aromatase Inhibitors Aromatase Inhibitors Tamoxifen Fulvestrant Fulvestrant AI s Progestin PFS* 9-13 mths 3-4 mths <3 mths Endocrine Resistance Alterations of ER itself Loss due to ESR1 silencing Constitutional activation of ER due to ESR1 mutations/ fusion events Up-regulation of alternative signal transduction pathways Source: MDACC (Hortobagyi, * S Johnston, SABCS 2016 plenary) 25
26 Hormonal agents have shown a consistent volume growth because of broad use, potentially extended duration of therapy and combo dosing SERD Unit Volume* 350,000, ,000, ,000, ,000, ,000,000 Unit Volume per Hormone Agent* 3,000,000 2,500,000 2,000,000 1,500,000 1,000, , ,000,000 50,000, AI SERM SERD Introduction of an Oral SERD will accelerate adoption across all lines of treatment and in combination therapies * IMS: NSP ( ) 26
27 Elacestrant Potential Opportunity in ER+ Breast Cancer Patient estimates: US only Illustrative example Adjuvant BC K pts Patient numbers 1 st L Adv BC 35-40K patients 2 nd L Adv BC 30-35K patients 3 rd L Adv BC 26-30K *Arimidex peak sales $1.9B *Current Faslodex (inj) $0.8B in sales Potential use of oral SERD either as mono or all oral combo regimens * Projected global sales 27
28 Highlights and Upcoming Milestones FDA Approval of TYMLOS April 28, 2017 CHMP opinion on MAA for abaloparatide-sc in July 2017 Ex-US/ROW partnership for abaloparatide-sc by time of EU launch Report topline results for 24 month ACTIVExtend trial Q2 17 FDA meeting scheduled for Ph 2 study for elacestrant Q2 17 Initiate first in human trial for RAD140 in HR+ breast cancer in 2H 17 28
SABCS 2017 WEBCAST. Elacestrant (RAD1901) Update. December 7, 2017
SABCS 2017 WEBCAST Elacestrant (RAD1901) Update December 7, 2017 NASDAQ: RDUS Disclaimer: Elacestrant is an investigational agent Please refer to the SABCS 2017 poster for complete details Safe Harbor
More informationRadius Highlights Science-Driven Biopharmaceutical Company
1 NASDAQ: RDUS Safe Harbor Any statements made in this presentation relating to future financial or business performance, conditions, plans, prospects, trends or strategies and other financial or business
More informationG1 Corporate Overview March 11, 2019
G1 Corporate Overview March 11, 2019 www.g1therapeutics.com NASDAQ: GTHX 1 Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements within the
More informationOutline of the presentation
Outline of the presentation Breast cancer subtypes and classification Clinical need in estrogen-positive (ER+) metastatic breast cancer (mbc) Sulforaphane and SFX-01: the preclinical evidence STEM Phase
More informationEndocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
More informationMechanisms of hormone drug resistance
Mechanisms of hormone drug resistance Ljiljana Stamatović Institute for Oncology and Radiology of Serbia Tenth UMOS Conference, Belgrade, 16-17 th May 2015. Hormone receptor-positive breast cancer (HR+
More informationInvestor Presentation
Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationMultimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationEndocrine Therapy for Advanced Breast Cancer (ABC) Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore
Endocrine Therapy for Advanced Breast Cancer (ABC) Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore Outline Guidelines and Evolving Clinical Treatment Landscape for HR+ HER2-
More informationHighlitghs in MBC First and second line endocrine treatments. Antonio Frassoldati Oncologia Clinica Ferrara
Highlitghs in MBC First and second line endocrine treatments Antonio Frassoldati Oncologia Clinica Ferrara Which clinical scenario have to face First line therapy with today? Untreated metastatic breast
More informationAggiornamenti tra ricerca e clinica: il carcinoma della mammella
Aggiornamenti tra ricerca e clinica: il carcinoma della mammella Filippo Montemurro Unit of (INCO) Fondazione del Piemonte per l Oncologia Candiolo Cancer Institute (IRCCs) Research Needs in Breast Cancer
More informationUpdate mbc. endokrine Therapie
Update mbc endokrine Therapie HR neg ER pos Endokrine Resistenz Endokrine Therapie 1 st line Postmenopause AI/Tam/Fulvestrant 84% AI+ Fulvestrant 33% AI (Tam) + Everolimus 84% AI + CDK4/6 92% Prämenopause
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationLeading the Next Wave of Biotech Breakthroughs
Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More information10/15/2012. Overcoming Endocrine Therapy Resistance. The Problem in ER+ Tumors is Endocrine Therapy Resistance
Overcoming Endocrine Therapy Resistance Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Slide Credits: Hope Rugo, MD The Problem in ER+ Tumors is Endocrine Therapy Resistance
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More informationClovis Oncology Announces First Quarter 2017 Operating Results. May 3, :06 PM ET
Clovis Oncology Announces First Quarter 2017 Operating Results May 3, 2017 4:06 PM ET Strong Q1 launch quarter for Rubraca (rucaparib) in U.S. with $7M reported in net sales Clovis notified that ARIEL3
More informationPredicting outcome in metastatic breast cancer
Predicting outcome in metastatic breast cancer Aleix Prat, MD, PhD Medical Oncology Department Translational Genomics and Targeted Therapeutics in Solid Tumors Monday, 15 th January, Manchester, UK Disclosures
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationMetastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationNY-ESO SPEAR T-cells in Synovial Sarcoma
NY-ESO SPEAR T-cells in Synovial Sarcoma ASCO Update June 6, 2017 Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationNovel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance
Novel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance Richard S. Finn, MD Division of Hematology/ Oncology Director, Translational Oncology Laboratory Geffen School of Medicine
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationRuth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory University, Chief of
Endocrine Therapy of Advanced Breast Cancer School of Breast Oncology November 9 th 2013 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology,
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationTargeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
2016.04.30 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationNewLink Genetics Corporation
Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationGenta Incorporated. A Multiproduct Late-Stage Oncology Company
Genta Incorporated A Multiproduct Late-Stage Oncology Company This presentation may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationManagement of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers
Review Article Page 1 of 10 Management of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers Roger K. C. Ngan Department of Clinical Oncology, Queen Elizabeth
More informationThird Quarter 2018 Financial Results. November 1, 2018
Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key
More informationMedia Contact: Ron Rogers Investor Contact: Scott Gleason (801) (801)
News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Receives FDA Approval of BRACAnalysis CDx as Companion
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationNew SEL-212 Phase 2 Data Presented at EULAR. June 15, 2018
New SEL-1 Phase Data Presented at EULAR June 15, 1 Safe Harbor / Disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ( the company
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationTranslating cancer biology into medicines BIO CEO Investor Conference NASDAQ CYCC - February 12, 2018
CYC 682 Translating cancer biology into medicines BIO CEO Investor Conference NASDAQ CYCC - February 12, 2018 Disclaimer This presentation contains forward-looking statements within the meaning of the
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2017 EARNINGS PRESENTATION MARCH 2018 1 Forward-looking statements disclosure This presentation contains
More informationObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase
More informationGSK Oncology R&D Update
GSK Oncology R&D Update Axel Hoos, MD Senior Vice President, Oncology R&D February 2019 Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements.
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017 1 Forward-looking statements disclosure This presentation contains
More informationPhase 3 Top-Line Results Show IBRANCE in Combination with Fulvestrant Meets Progression-Free Survival (PFS) Primary Endpoint
For immediate release: April 15, 2015 Media Contact: Sally Beatty (212) 733-6566 Investor Contact: Ryan Crowe (212) 733-8160 Pfizer Announces PALOMA-3 Trial for IBRANCE (Palbociclib) Stopped Early Due
More informationAgents in the Treatment of ER+ Aromatase Inbitor-Resistant Metastatic Breast Cancer: M-THOR Inhibitors
Agents in the Treatment of ER+ Aromatase Inbitor-Resistant Metastatic Breast Cancer: M-THOR Inhibitors Valero, M.D., Professor of Medicine and Deputy Chairman Department of Breast Medical Oncology The
More informationPro: Hormone Therapy in HR positive MBC is the preferred option!
Pro: Hormone Therapy in HR positive MBC is the preferred option! Alexandru Eniu, MD, PhD Medical Oncologist Head, Day Hospital Unit Department of Breast Tumors Cancer Institute Ion Chiricuţă Cluj-Napoca,
More informationBuilding a Leading Oncology Franchise
ASDAQ: MEIP Building a Leading Oncology Franchise 17th Annual eedham Healthcare Conference March 27, 2018 Forward-Looking Statements This presentation contains, and our officers and representatives may
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationARQ 087 Overview. FGFR Inhibitor. March 2017
ARQ 087 Overview FGFR Inhibitor March 2017 Safe Harbor This presentation and other statements by ArQule contain forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationFORWARD II PROGRAM UPDATE
FORWARD II PROGRAM UPDATE NASDAQ: IMGN May 17, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements based on management's current expectations. These statements include,
More informationPRO 140. First self-administered antibody therapy for HIV in late-stage clinical development. March
PRO 140 First self-administered antibody therapy for HIV in late-stage clinical development March 2018 Forward-Looking Statements This presentation includes forward-looking statements and forward-looking
More informationEndoxifen Clinical Update February 1, 2018
Endoxifen Clinical Update February 1, 2018 107 Spring Street Seattle, WA 98104 USA Forward-looking Statements Some of the information presented herein may contain projections or other forward-looking statements
More informationPage. Objectives: Hormone Therapy Resistance: Challenges and Opportunities. Research Support From Merck
Hormone Therapy Resistance: Challenges and Opportunities Pamela. N. Munster, MD University of California, San Francisco Financial Disclosures Research Support From Merck Objectives: Understanding the current
More informationZogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008
More informationFOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE. Thursday, February 7, 2019
FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE Thursday, February 7, 2019 Today s Speakers Overview and Key Highlights Clay Siegall, President & CEO Financial Results and Guidance
More informationMetastatic HR+ Breast Cancer - CDK 4/6 Inhibitors Charting the Path. Sandy Sehdev MD FRCPC
Metastatic HR+ Breast Cancer - CDK 4/6 Inhibitors Charting the Path Sandy Sehdev MD FRCPC Objectives To understand the approach to the treatment of hormone sensitive metastatic breast cancer and the use
More informationMerrimack Pharmaceuticals: A Refocused R&D Company January 2017
Merrimack Pharmaceuticals: A Refocused R&D Company January 2017 Forward Looking Statements This presentation contains forward-looking statements of the Company that involve substantial risks and uncertainties.
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationInibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici Laura Orlando UOC Oncologia & Breast Unit Brindisi Verona 22/04/2016 Summary Studi con
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationInfinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results
Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,
More informationIntroduction. Ahmad Radzi 1*, Fabian Wei Luen Lee 2 REVIEW ARTICLE
doi: 10.18282/amor.v4.i1.255 REVIEW ARTICLE Optimizing treatment-sequencing strategies for the management of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: A
More informationTheravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation
Theravance Announces Positive Results from Phase 1 and Phase 2 Clinical Studies with TD-1211 in Development for Opioid-Induced Constipation TD-1211 Achieves Primary and Secondary Endpoints SOUTH SAN FRANCISCO,
More informationIpilimumab ASCO Data Review and Discussion Webcast. Monday, June 2, 2008
Ipilimumab ASCO Data Review and Discussion Webcast Monday, June 2, 2008 Slide 2 Forward Looking Statements Except for historical information, the matters contained in this slide presentation may constitute
More informationASCO 2018 investor event; breakout 2: Lynparza lifecycle; MRK collaboration
ASCO 208 investor event; breakout 2: Lynparza lifecycle; MRK collaboration Hyatt Conference Columbus208 Klaus Edvardsen, Senior Vice President, Head of Oncology, Global Medicines Development 04 June 208
More informationMyeloid Differentiation Observed, Including Induction of CD38 in 85% of Evaluable Patients
December 10, 2017 Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients Clinical
More informationSyndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab)
Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) Ongoing ENCORE 601 biomarker analyses suggest enhanced clinical benefit in subpopulation
More informationBuilding a Premier Oncology Biotech
Corporate Presentation Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO February 2019 Forward-Looking Statements All of the statements in this presentation that are not statements
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More information